GLI1 and neoplasm: A significant longer survival period was also observed for mice with tumours derived from Caov3 SHH-OE cells co-injected with CAFs Gli1-shRNA compared to that of mice with tumours derived from Caov3 SHH-OE cells co-injected with CAFs shNC (Figure 7D).